Fusion Pharmaceuticals
109 articles about Fusion Pharmaceuticals
-
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
3/20/2024
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on clinical and corporate developments.
-
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
3/19/2024
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates.
-
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
3/19/2024
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.
-
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2024
3/6/2024
Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 245,300 shares.
-
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
3/5/2024
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
-
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
2/26/2024
Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.
-
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
2/16/2024
Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.
-
Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer
5/2/2023
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility.
-
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
4/20/2023
Fusion Pharmaceuticals Inc. announced that the Company will present in a company presentation at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 3:00 p.m. ET.
-
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting
4/19/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced the presentation of preclinical data that provide further support of its clinical stage FPI-2059, a neurotensin receptor 1 (NTSR1) targeted alpha therapy (TAT), and additional preclinical development programs.
-
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
4/12/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced the clearance of investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107) to the U.S. Food and Drug Administration (FDA).
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2023
4/5/2023
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 258,000 shares of its common stock to four employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
3/20/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the Phase 1 study evaluating [225Ac]-FPI-2059 (FPI-2059).
-
Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates
3/16/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an update on clinical and corporate developments.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 8, 2023
3/8/2023
Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 21,000 shares.
-
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
3/2/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a panel titled, "Novel Oncology Targets" at the 43rd Annual Cowen Healthcare Conference on Tuesday, March 7, 2023 at 9:10 a.m. ET.
-
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
2/13/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 p.m. ET.
-
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
2/13/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion") today announced the acquisition from RadioMedix, Inc. ("RadioMedix") of the investigational new drug application ("IND") for an ongoing Phase 2 clinical trial (the "TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 07, 2023
2/7/2023
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 161,000 shares of its common stock to two employees outside Fusion's 2020 Stock Option and Incentive Plan.